<DOC>
	<DOCNO>NCT00061867</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , liposomal doxorubicin , use different way stop tumor cell divide stop grow die . Microwave thermotherapy kill tumor cell heat several degree body temperature . Combining liposomal doxorubicin microwave thermotherapy may kill tumor cell . PURPOSE : This phase I trial study side effect best dose liposomal doxorubicin give together microwave thermotherapy treating patient prostate cancer .</brief_summary>
	<brief_title>Liposomal Doxorubicin Thermal Therapy Treating Patients With Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose doxorubicin HCl liposome release thermal microwave therapy patient adenocarcinoma prostate . - Determine pharmacokinetics biodistribution profile drug patient . - Determine safety profile dose-limiting toxicity drug patient . - Determine clinical response patient treat regimen . OUTLINE : This open-label , dose-escalation , multicenter study . Patients receive doxorubicin HCl liposome IV 30 minute . Patients undergo 60-minute course prostate thermotherapy . Treatment may repeat every 28-42 day 6 course , discretion physician . Cohorts 3-6 patient receive escalate dos doxorubicin HCl liposome maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 3 2 6 patient experience dose-limiting toxicity . Patients follow 8 , 15 , 30 , 90 day . PROJECTED ACCRUAL : Approximately 50 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate Rising prostatespecific antigen AND radiographic evidence extraprostatic prostate cancer bone scan , CT scan , prostascint scan , MRI PATIENT CHARACTERISTICS : Age 40 Performance status Karnofsky 80100 % Life expectancy Not specify Hematopoietic WBC great 4,000/mm^3 Platelet count great 100,000/mm^3 Hemoglobin great 10.0 g/dL Hepatic Bilirubin normal AST normal Alkaline phosphatase normal No acute chronic liver disease Renal Creatinine less 1.5 time upper limit normal Cardiovascular Ejection fraction least 50 % MUGA EKG normal No myocardial infarction cerebral vascular accident within past 6 month No life threaten cardiac arrhythmia No congestive heart failure No cardiac pacemaker No peripheral arterial disease intermittent claudication Leriches syndrome ( i.e. , claudication buttock perineum ) Other Fertile patient must use effective barrier contraception 3 month study participation No sperm donation 3 month study participation Not febrile No interest future fertility father child No significantly decrease pain response No severe urethral stricture No protruding median lobe result `` ballvalve '' type obstruction bladder neck No major psychiatric illness would prevent informed consent No major psychiatric illness require inpatient treatment within past 3 month No psychological , family , sociological , geographic condition would preclude study compliance No allergy egg egg product No urinary prostatic infection No full urinary retention No penile urinary sphincter implant No metallic implant pelvic femoral area No serious medical illness would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent live vaccine Chemotherapy No prior anthracycline No concurrent streptozocin Endocrine therapy No concurrent hormonal therapy ( except luteinizing hormonereleasing hormone analog ) No concurrent glucocorticoid administer physiologic replacement dos ( antiemetic ) Radiotherapy Not specify Surgery More 3 month since prior major surgery Other No prior therapy result permanent reduction pain response ( e.g. , prior surgery , regional local anesthetic ) No concurrent PCSPES No concurrent cyclosporine , phenobarbital , phenytoin</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2005</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
</DOC>